RU2012127811A - Способ получения клеток-натуральных киллеров и дендритных клеток из человеческих эмбриональных гемангиобластов, полученных из стволовых клеток - Google Patents

Способ получения клеток-натуральных киллеров и дендритных клеток из человеческих эмбриональных гемангиобластов, полученных из стволовых клеток Download PDF

Info

Publication number
RU2012127811A
RU2012127811A RU2012127811/10A RU2012127811A RU2012127811A RU 2012127811 A RU2012127811 A RU 2012127811A RU 2012127811/10 A RU2012127811/10 A RU 2012127811/10A RU 2012127811 A RU2012127811 A RU 2012127811A RU 2012127811 A RU2012127811 A RU 2012127811A
Authority
RU
Russia
Prior art keywords
cells
hemangioblasts
approximately
scf
days
Prior art date
Application number
RU2012127811/10A
Other languages
English (en)
Russian (ru)
Inventor
Эрин КИМБРЕЛЛ
Си-Цзян ЛЮ
Original Assignee
Стем Селл Энд Ридженерэйтив Медсин Интернэшнл, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стем Селл Энд Ридженерэйтив Медсин Интернэшнл, Инк. filed Critical Стем Селл Энд Ридженерэйтив Медсин Интернэшнл, Инк.
Publication of RU2012127811A publication Critical patent/RU2012127811A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RU2012127811/10A 2009-12-04 2010-12-01 Способ получения клеток-натуральных киллеров и дендритных клеток из человеческих эмбриональных гемангиобластов, полученных из стволовых клеток RU2012127811A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26666109P 2009-12-04 2009-12-04
US61/266,661 2009-12-04
PCT/US2010/058593 WO2011068896A1 (en) 2009-12-04 2010-12-01 Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts

Publications (1)

Publication Number Publication Date
RU2012127811A true RU2012127811A (ru) 2014-01-10

Family

ID=44115272

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012127811/10A RU2012127811A (ru) 2009-12-04 2010-12-01 Способ получения клеток-натуральных киллеров и дендритных клеток из человеческих эмбриональных гемангиобластов, полученных из стволовых клеток

Country Status (11)

Country Link
US (3) US8822218B2 (enExample)
EP (1) EP2507365A4 (enExample)
JP (5) JP6013187B2 (enExample)
KR (5) KR20190016602A (enExample)
CN (1) CN102822332A (enExample)
AU (1) AU2010326027A1 (enExample)
BR (1) BR112012014104A2 (enExample)
CA (3) CA3095576A1 (enExample)
IN (1) IN2012DN05053A (enExample)
RU (1) RU2012127811A (enExample)
WO (1) WO2011068896A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
BR112012014104A2 (pt) 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
WO2013163171A1 (en) * 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
WO2015100495A1 (en) * 2014-01-03 2015-07-09 FullHope Biomedical Co., Ltd. Modified natural killer cells, compositions and uses thereof
CN105219710B (zh) * 2014-06-05 2020-01-10 上海厚超生物科技有限公司 一种高杀伤活性的免疫细胞群的培养方法
DE102014014993B4 (de) * 2014-10-09 2017-02-02 Helga Schmetzer Verwendung von immunmodulatorisch wirksamen Kits zur immuntherapeutischen Behandlung von Patienten mit myeloischen Leukämien
CN104711225B (zh) * 2015-04-09 2018-05-22 奥思达干细胞有限公司 Nk细胞的体外制备方法
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
CN105219716A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活头颈部癌特异性免疫反应的试剂盒
CN105219728A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活乳腺癌特异性免疫反应的试剂盒
CN105219717A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种一型极化树突状细胞及其诱导方法和应用
CN105219719A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活卵巢癌特异性免疫反应的试剂盒
CN105219726A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种高效制备一型极化树突状细胞的方法及其应用
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
CN105219722A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肾癌特异性免疫反应的试剂盒
CN105219727A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活结直肠癌特异性免疫反应的试剂盒
CN105219718A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活前列腺癌特异性免疫反应的试剂盒
CN105219725A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肉瘤特异性免疫反应的试剂盒
KR102167548B1 (ko) * 2017-09-21 2020-10-19 한국생명공학연구원 자연살해세포의 제조방법 및 그의 용도
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
CN113166726A (zh) 2019-07-08 2021-07-23 南克维斯特公司 单核细胞源性nk细胞
US11547726B2 (en) * 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
TW202216744A (zh) 2020-07-20 2022-05-01 美商維埃拉生物股份有限公司 用於治療自體免疫性病症和炎性病症之免疫細胞介素
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
KR102292843B1 (ko) * 2020-12-29 2021-08-25 주식회사 온코인사이트 역분화줄기세포(iPSC) 유래 자연 살해 세포 및 이의 용도
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
EP4581132A1 (en) * 2022-09-02 2025-07-09 Imperial College Innovations Limited Natural killer cells
CN120344654A (zh) 2022-12-29 2025-07-18 安斯泰来制药有限公司 改造的自然杀伤细胞和相关方法
WO2025212519A1 (en) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201102T3 (es) * 1994-06-15 2004-03-16 Systemix, Inc. Poblaciones de celulas enriquecidas en progenitores mieloides y/o linfoides y metodos de elaboracion y uso.
CA2278847A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
AU7499498A (en) * 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
WO1999028486A1 (en) * 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
FR2801056B1 (fr) * 1999-11-12 2003-03-28 Commissariat Energie Atomique Proteine presente a la surface des cellules souches hematopoietiques de la lignee lymphoide et des cellules nk, et ses applications
KR20020083634A (ko) * 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
US20050042751A1 (en) * 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
US20060239962A1 (en) * 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
WO2004090112A2 (en) * 2003-04-01 2004-10-21 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2005049812A1 (en) * 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
WO2005085426A1 (ja) * 2004-03-04 2005-09-15 Tanabe Seiyaku Co., Ltd. 無フィ−ダ−分化用培地及び霊長類動物胚性幹細胞からの無フィ−ダ−分化方法
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
DE602005025005D1 (de) * 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US20080166751A1 (en) * 2005-02-23 2008-07-10 Takayuki Asahara Method of Analyzing Dynamics in the Differentiation of Vascular Endothelial Progenitor Cells
AU2006249640C1 (en) * 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
KR20080015033A (ko) * 2005-06-01 2008-02-15 위스콘신 얼럼나이 리서어치 화운데이션 배아 줄기 세포로부터 가지 세포를 형성하는 방법
PT1941027E (pt) * 2005-09-28 2014-10-09 Ipd Therapeutics B V Métodos e meios para proliferação de células estaminais e subsequente geração e expansão de células progenitoras, bem como produção de células efectoras como produtos terapêuticos clínicos
AU2007238660C1 (en) * 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
WO2008038279A2 (en) * 2006-09-25 2008-04-03 Kfir Nissan Force transducer and method
EP2088190A4 (en) 2006-11-09 2011-01-05 Japan Government METHOD FOR THE CULTURE AND PASSING OF AN EMBRYONAL PRIMATIVE STEM CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF THE EMBRYONAL STEM CELL
DE102006054041B3 (de) * 2006-11-16 2008-05-08 Pierburg Gmbh Regelvorrichtung für eine Verbrennungskraftmaschine
EP2203176B1 (en) * 2007-09-28 2014-11-26 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2009120891A2 (en) * 2008-03-27 2009-10-01 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
US20110086424A1 (en) 2008-05-06 2011-04-14 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
BRPI0912201A2 (pt) 2008-05-06 2019-09-24 Advanced Cell Tech Inc células formadoras de colônias de hemangios e células de hemangio não enxertantes
CA2753679C (en) * 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
BR112012014104A2 (pt) 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco

Also Published As

Publication number Publication date
EP2507365A4 (en) 2014-01-01
WO2011068896A1 (en) 2011-06-09
CA3080368A1 (en) 2011-06-09
JP2019083819A (ja) 2019-06-06
CA3095576A1 (en) 2011-06-09
BR112012014104A2 (pt) 2016-07-05
KR20210120136A (ko) 2021-10-06
JP6013187B2 (ja) 2016-10-25
JP2016119910A (ja) 2016-07-07
CA2781969A1 (en) 2011-06-09
US20200131475A1 (en) 2020-04-30
US8822218B2 (en) 2014-09-02
US20150140657A1 (en) 2015-05-21
JP2024177183A (ja) 2024-12-19
KR20120112511A (ko) 2012-10-11
EP2507365A1 (en) 2012-10-10
KR20250048382A (ko) 2025-04-08
US20120282693A1 (en) 2012-11-08
IN2012DN05053A (enExample) 2015-10-09
KR20200083645A (ko) 2020-07-08
JP2013512673A (ja) 2013-04-18
CN102822332A (zh) 2012-12-12
KR101947588B1 (ko) 2019-02-14
KR20190016602A (ko) 2019-02-18
JP2022027790A (ja) 2022-02-14
JP7343984B2 (ja) 2023-09-13
AU2010326027A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
JP2013512673A5 (enExample)
JP7687634B2 (ja) 培地組成物及び当該組成物を用いた細胞又は組織の培養方法
US20220228118A1 (en) Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
US20240279597A1 (en) Culture medium composition and method of culturing cell or tissue using thereof
RU2008141279A (ru) Способы сохранения, улучшения и восстановления хрящевого фенотипа хондроцитов
RU2012127810A (ru) Крупномасштабное получение функциональных мегакариоцитов и тромбоцитов из человеческих эмбриональных стволовых клеток в бесстромальных условиях
CN109082411A (zh) 一种通过多能干细胞分化获得具有吞噬功能的巨噬细胞的方法
JP6909154B2 (ja) 幹細胞組成物および療法適用のための幹細胞を産生する方法
CN100545260C (zh) 人羊膜间充质干细胞的分离及培养方法及医用组合物
CN106282108A (zh) 一种具有免疫调节功能的脾脏间充质干细胞及其制备方法与应用
EP2454363B1 (en) Method for using directing cells for specific stem/progenitor cell activation and differentiation
CN101173247A (zh) 一种利用间充质干细胞联合细胞因子培养破骨细胞的方法
CN105062960B (zh) 一种牙周膜干细胞原代分离及培养方法
CN103525761B (zh) 分离培养动物骨髓间充质干细胞的方法
JP2011211956A (ja) 幹細胞の未分化維持剤及び増殖促進剤
CN103820386B (zh) 促进间充质干细胞体外增殖及延缓衰老的活性基质胶
CN1676603A (zh) 一种人骨髓间充质干细胞体外扩增的新方法
WO2014135949A2 (en) Novel method of progenitor cell expansion
US20130189233A1 (en) Method for using directing cells for specific stem/progenitor cell activation and differentiation
TW201111502A (en) Method for extracting mesenchymal stem cell from embryo of animals and human, and method for extracting secretion from the extracting mesenchymal stem cell
Huard Revised Manuscript# E05-02-0169 Title Page
CN106318911A (zh) 一种用于大量扩增pd‑1基因重组活化t细胞的培养基、试剂盒及其应用
CN103667180A (zh) 一种人角质干细胞体外诱导分化为人毛囊细胞的方法
HK1218927B (en) Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
HK1210807B (en) Culture medium composition, and method for culturing cell or tissue using said composition

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20131202